Urogen Pharma (NASDAQ:URGN) Announces Earnings Results

Urogen Pharma (NASDAQ:URGN) released its earnings results on Monday. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.12, FiscalAI reports. The business had revenue of $37.84 million for the quarter, compared to analysts’ expectations of $39.92 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• Company says the permanent J-code (effective Jan 1, 2026) removed a key adoption barrier and management reports clear early‑2026 acceleration in new and repeat prescribers, patient enrollment forms and new patient starts, with management projecting > $1 billion potential peak revenue for Zusduri based on its assumptions.
• The next‑generation program UGN‑103 achieved a 77.8% complete response at 3 months in the Phase 3 UTOPIA trial, and UroGen plans an NDA submission in H2 2026 with potential FDA approval in 2027 while evaluating adjuvant and high‑grade indications.
• UroGen refinanced its term loan, receiving an initial $200 million (up to $250 million available), fixed the interest rate at 8.25%, and extended principal repayment to 2030, which management says strengthens financial flexibility to support the launch and pipeline.
• The company reported a 2025 net loss of $153.5 million, expects 2026 operating expenses of $240–$250 million, and held $120.5 million in cash and marketable securities as of Dec 31, 2025, signaling ongoing losses and funding needs despite the refinancing.
• Management provided 2026 guidance for Jelmyto net product revenue ($97–$101 million) but is withholding formal 2026 sales guidance for Zusduri until it gains greater visibility (expects to reassess roughly two quarters after the permanent J‑code).

Urogen Pharma Trading Down 1.1%

Shares of Urogen Pharma stock opened at $18.82 on Wednesday. The firm has a fifty day simple moving average of $21.10 and a 200-day simple moving average of $20.87. The stock has a market capitalization of $880.96 million, a price-to-earnings ratio of -5.88 and a beta of 1.34. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00.

Analyst Ratings Changes

A number of research firms have issued reports on URGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research report on Monday. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research report on Monday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.29.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 7,373 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider directly owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the transaction, the general counsel owned 51,326 shares in the company, valued at $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP lifted its holdings in shares of Urogen Pharma by 6.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after buying an additional 257,564 shares during the last quarter. Morgan Stanley raised its stake in Urogen Pharma by 1.4% during the 4th quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock valued at $60,023,000 after purchasing an additional 34,455 shares during the last quarter. Soleus Capital Management L.P. bought a new stake in Urogen Pharma in the 2nd quarter valued at $29,934,000. MPM Bioimpact LLC grew its position in Urogen Pharma by 597.3% in the 4th quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock worth $22,047,000 after purchasing an additional 806,378 shares during the last quarter. Finally, Orbimed Advisors LLC increased its holdings in shares of Urogen Pharma by 27.1% during the 4th quarter. Orbimed Advisors LLC now owns 875,487 shares of the company’s stock worth $20,504,000 after purchasing an additional 186,487 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.